NBIX
Neurocrine Biosciences Inc
Neurocrine Biosciences Inc historical holders
total: 1
Dodge & Cox Stock Fund Neurocrine Biosciences Inc transactions over time
- Total transactions:
- 5
- New positions:
- 1
- Added:
- 4
- Held since:
- 2023 Q3
- Held for:
- 11 quarters
- Latest activity:
- 2025 Q1
Dodge & Cox Stock Fund has been an institutional investor in Neurocrine Biosciences Inc (NBIX) since 2023 Q3. According to 2026 Q1 report, Dodge & Cox Stock Fund holds 3,964,000 shares with a market value of roughly $522.22M representing 0.46% of their equity portfolio. The fund/company first acquired NBIX in 2023 Q3, initially purchasing 142,330 shares. Since the initial investment, Dodge & Cox Stock Fund has made 4 more transactions in this position.
Does Dodge & Cox Stock Fund still hold NBIX?
Yes, Dodge & Cox Stock Fund continues to hold Neurocrine Biosciences Inc (NBIX). According to their 2026 Q1 report, they maintain a position of 3,964,000 shares valued at approximately $522.22M, representing 0.46% of their equity portfolio.
When did Dodge & Cox Stock Fund first invest in NBIX?
Dodge & Cox Stock Fund first invested in Neurocrine Biosciences Inc (NBIX) in 2023 Q3 at the reported quarter-end price of $112.50 per share, acquiring 142,330 shares in their initial purchase.
What is Dodge & Cox Stock Fund's average cost basis for NBIX?
Based on historical transaction data, Dodge & Cox Stock Fund's estimated cost basis for Neurocrine Biosciences Inc (NBIX) is approximately $121.95 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $121.95
NBIX transactions history by Dodge & Cox Stock Fund
5 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q1
|
0.39%
|
3,964,000
|
$110.60
|
$438,418,400
|
+101.28% (+1,994,564)
|
+0.19%
|
|
2024 Q4
|
0.24%
|
1,969,436
|
$136.50
|
$268,828,014
|
+181.23% (+1,269,148)
|
+0.16%
|
|
2024 Q2
|
0.09%
|
700,288
|
$137.67
|
$96,408,649
|
+0.74% (+5,140)
|
+0%
|
|
2023 Q4
|
0.09%
|
695,148
|
$131.76
|
$91,592,700
|
+388.41% (+552,818)
|
+0.07%
|
|
2023 Q3
|
0.02%
|
142,330
|
$112.50
|
$16,012,125
|
new
|
+0.02%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.